Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SG 500455

Next Previous
X
Search
Drug Profile

SG 500455

Alternative Names: SG-2-0776; SG-5-00455

Latest Information Update: 16 Mar 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Second Genome
  • Developer Mayo Clinic; Second Genome
  • Class Anti-inflammatories; Antifibrotics; Bacteria; Gene therapies; Peptides
  • Mechanism of Action Bacteria replacements; Plasminogen activator inhibitor-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Inflammatory bowel diseases

Most Recent Events

  • 16 Mar 2023 Preclinical development is ongoing for Inflammatory-bowel-diseases in USA (PO) (Second Genome pipeline, March 2023)
  • 18 Feb 2022 Pharmacodynamics data from a preclinical trial in Inflammatory bowel disease released by Second Genome
  • 10 Feb 2022 Second Genome announces intention to file an IND application for Inflammatory bowel diseases in the second half of 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top